WW International Inc. (NASDAQ:WW) said its Med+ members will gain access to reduced pricing for Wegovy through an expanded collaboration with Novo Nordisk (NYSE:NVO), lowering out-of-pocket costs for patients paying without insurance.
The program gives Weight Watchers Med+ members access to subscription-based pricing for Wegovy doses, potentially delivering savings of up to $1,200 per year for individuals paying in cash. The initiative aligns with Novo Nordisk’s recently introduced subscription pricing model for the obesity treatment.
Eligible Med+ members who have valid prescriptions can prepay for three-, six-, or 12-month supplies of Wegovy at discounted monthly rates. The program applies to Wegovy injection pens across all dosage levels and Wegovy tablets at 9 mg and 25 mg doses. Depending on the length of the commitment, members may save up to $100 per month on injection pens and up to $50 per month on tablets compared with standard self-pay pricing.
“Novo Nordisk and Weight Watchers are each committed to helping those living with obesity take control of their health–and we are strengthening our collaboration to support that shared mission,” said Ed Cinca, Senior Vice President Marketing and Patient Solutions at Novo Nordisk.
Members who do not opt for multi-month plans can still access current promotional offers, including introductory Wegovy tablet doses priced at $149 per month. Weight Watchers participates in the NovoCare program as a Recognized Care Provider.
The Weight Watchers Med+ platform connects members with board-certified physicians, access to FDA-approved prescriptions, and structured lifestyle programs. Its GLP-1 Success initiative provides additional tools and guidance throughout a patient’s treatment journey.
The company said its clinical services segment is expanding rapidly as demand rises for integrated GLP-1-based weight management programs. The strengthened partnership with Novo Nordisk builds on the companies’ existing collaboration to broaden access to approved treatments for obesity management.